News | March 02, 2026
Blue Jet Healthcare breaks ground on Rs. 2,300 crore pharma plant in Andhra Pradesh
The facility is expected to become operational by FY2028-29
The facility is expected to become operational by FY2028-29
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Subscribe To Our Newsletter & Stay Updated
